MiReven receives further investment from MRCF
Two high profile R&D collaborations including one with Silence Therapeutics
29-Aug-2012 -
MiReven, an Australian microRNA company commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7, announced that it had received a further AU$500K investment from the Medical Research Commercialisation Fund (MRCF) due to ...
cancer
microRNAs